|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2010-9-9
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Long-term side-effects and cost of HIV treatment motivate the development of simplified maintenance. Monotherapy with ritonavir-boosted lopinavir (LPV/r-MT) is the most widely studied strategy. However, efficacy of LPV/r-MT in compartments remains to be shown.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2347-54
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20802298-Adult,
pubmed-meshheading:20802298-CD4 Lymphocyte Count,
pubmed-meshheading:20802298-Drug Administration Schedule,
pubmed-meshheading:20802298-Drug Combinations,
pubmed-meshheading:20802298-Female,
pubmed-meshheading:20802298-HIV Infections,
pubmed-meshheading:20802298-HIV Protease Inhibitors,
pubmed-meshheading:20802298-HIV-1,
pubmed-meshheading:20802298-Humans,
pubmed-meshheading:20802298-Lopinavir,
pubmed-meshheading:20802298-Male,
pubmed-meshheading:20802298-Middle Aged,
pubmed-meshheading:20802298-Pyrimidinones,
pubmed-meshheading:20802298-RNA, Viral,
pubmed-meshheading:20802298-Ritonavir,
pubmed-meshheading:20802298-Semen,
pubmed-meshheading:20802298-Time Factors,
pubmed-meshheading:20802298-Treatment Failure,
pubmed-meshheading:20802298-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.
|
|
pubmed:affiliation |
Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
